The three largest direct-to-consumer telehealth weight loss platforms — Ro Body, Hims & Hers Weight Loss, and Henry Meds — charge meaningfully different amounts for what is often the same underlying medication. Based on publicly listed prices as of April 2026, monthly out-of-pocket costs range from roughly $179 to over $450 depending on the platform, the drug, and the dose tier. For patients paying without insurance, that spread represents thousands of dollars annually.
How each platform structures its pricing
Ro Body bundles its program fee with compounded semaglutide, quoting a starting price of approximately $199 per month for lower maintenance doses, with higher doses running closer to $299 to $349 monthly based on Ro's published pricing tiers. The program fee covers asynchronous provider visits and ongoing messaging support. Hims & Hers takes a similar bundled approach, listing compounded semaglutide programs starting around $199 per month at introductory doses, though publicly listed prices for higher-dose tiers reach $299 or more. Henry Meds operates differently: it charges a flat $197 monthly membership that covers the provider relationship and medication, with compounded semaglutide included at doses up to a standard maintenance level. Patients requiring escalating doses may encounter additional charges on that platform.
Where compounded versus brand-name drugs change the math
All three platforms have relied heavily on compounded semaglutide — a legal gray area that narrowed considerably after the FDA removed semaglutide from its drug shortage list in late 2024. As of early 2026, FDA enforcement guidance and ongoing litigation have created platform-specific differences in what is actually dispensed. Ro and Hims have both publicly described transitions toward FDA-approved branded products for some patient segments, which carries dramatically higher list prices — Ozempic and Wegovy carry list prices above $900 per month without a manufacturer coupon or insurance coverage. Henry Meds has continued to emphasize compounded formulations where legally permissible. Patients should verify directly with each platform what drug they will actually receive before comparing monthly quotes, since the same advertised price may correspond to different products depending on when a patient enrolls.
Hidden costs that don't appear in headline prices
Each platform charges for the initial clinical consultation, though the treatment is typically structured so that fee is embedded in the first month's total. What varies is how platforms handle dose escalations, lab work requirements, and cancellation terms. Ro requires patients to complete a health intake and may recommend lab panels through third-party partners, which can add $50 to $100 in out-of-pocket costs not reflected in the monthly subscription quote. Hims & Hers has historically offered promotional introductory pricing that steps up after the first two or three months; the publicly listed ongoing rate is what matters for annual cost calculations. Henry Meds does not bill separately for provider visits within its membership model, which is a structural advantage for patients who need frequent check-ins or dose adjustments.
What insurance and employer benefits cover
None of the three platforms accepts traditional insurance for their subscription or compounded medication costs. However, Ro and Hims both have mechanisms to generate prior authorization documentation for patients who want to pursue brand-name GLP-1 coverage through their own insurer separately. Some large employer health plans and pharmacy benefit managers have added GLP-1 coverage with preferred pricing through specific telehealth channels — CVS Caremark and Express Scripts have both announced employer partnerships that create alternative cost structures outside the direct-to-consumer programs compared here. For patients with employer coverage that includes GLP-1 drugs, the telehealth platform route is frequently more expensive than using an in-network prescriber paired with insurance.
The bottom line on annual costs
For a patient paying entirely out of pocket and staying on compounded semaglutide for 12 months, Henry Meds projects to the lowest annual cost at roughly $2,364 based on its flat-rate structure, assuming no dose-related surcharges. Ro Body and Hims both project to approximately $2,388 to $4,188 annually depending on which dose tier applies. The gap widens significantly if either platform transitions a patient to branded semaglutide without insurance coverage, pushing annual costs above $10,000 at list price. The most important variable in any cost comparison for 2026 is not the platform's headline monthly rate — it is whether the patient will receive a compounded or branded product and whether their dose is likely to increase over time.